Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | PTAFR | P25105 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18971914 | 1.00 | TACR1 (0.59) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL20530562 | 0.91 | TACR1 (0.63) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL18971987 | 0.91 | TACR1 (0.63) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL20530522 | 0.91 | TACR1 (0.59) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL18971959 | 0.91 | TACR1 (0.59) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL20530527 | 0.91 | TACR1 (0.59) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL18971859 | 0.91 | TACR1 (0.59) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL20530521 | 0.91 | TACR1 (0.59) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL20530520 | 0.91 | TACR1 (0.60) | TACR1CYP3A4SIGMAR1PTAFR | |
| SCHEMBL20530500 | 0.88 | TACR1 (0.60) | TACR1CYP3A4SIGMAR1PTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388423-B1 | NK1 RECEPTOR ANTAGONIST | KISSEI PHARMACEUTICAL (JP) | 2020-05-27 | — | — | EP | disclosed |
| US-10399949-B2 | NK1 receptor antagonist | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20190002414-A1 | NK1 RECEPTOR ANTAGONIST | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| EP-3388423-A1 | NK1 RECEPTOR ANTAGONIST | Kissei Pharmaceutical Co., Ltd. (JP) | 2018-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002414-A1 | NK1 RECEPTOR ANTAGONIST | TACR1, TACR2, GRPR | TACR1 1/4885CYP3A4 2813/4885SIGMAR1 109/4885 |
| US-10399949-B2 | NK1 receptor antagonist | TACR1, TACR2, GRPR | TACR1 1/4885CYP3A4 2813/4885SIGMAR1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.